Exenatide and glucagon co-infusion increases myocardial glucose uptake and improves markers of diastolic dysfunction in adults with type 2 diabetes.
Exenatide and glucagon co-infusion may increase myocardial glucose uptake and improve certain markers of heart function in adults with type 2 diabetes, but further research is needed to confirm these effects and their clinical significance.
Where it sits
this study against the rest of the mazdutide (ibi362) corpusSummary and findings
This study evaluated the effects of exenatide and glucagon co-infusion on myocardial glucose uptake and diastolic function in eight adults with type 2 diabetes. Participants received a glucagon infusion at 12.5 ng/kg/min and exenatide at a loading dose of 50 ng/min for 30 minutes, followed by 25 ng/min. Results indicated an increase in myocardial glucose uptake and diastolic function markers, but further studies are needed to assess clinical implications.
Abstract
Type 2 diabetes (T2D) significantly increases the risk of heart failure, a major cause of hospitalisation and increased morbidity and mortality. Dual and multi-agonist synthetic peptides at the GLP-1 and glucagon receptor are in clinical development as potential new treatments for a range of chronic metabolic conditions including T2D. Here, we aimed to explore the effects of GLP-1 and glucagon dual receptor agonism on myocardial glucose uptake (MGU) and myocardial function in T2D. Eight adults with a mean age of 52 ± 12 years and body mass index 31 ± 4 kg/m<sup>2</sup> attended three randomised infusion visits using combinations of 0.9% saline, glucagon (12.5 ng/kg/min) and exenatide:glucagon co-infusion (exenatide loading dose 50 ng/min for 30 min then 25 ng/min). MGU and myocardial function were assessed using <sup>18</sup>F-FDG PET-MRI. MGU increased in n = 7/8 (88%) participants from a median of 9.2 × 10<sup>-3</sup> µmol/g/min (IQR 0.33-19 × 10<sup>-3</sup> µmol/g/min) with saline, to 20 × 10<sup>-3</sup> µmol/g/min (5.4-98 × 10<sup>-3</sup> µmol/g/min) with exenatide:glucagon, n = 8, z = 2.24, r = 0.79, P < 0.05. Exenatide:glucagon significantly increased the median left ventricular global peak diastolic circumferential strain rate from 0.619 1/s (0.580-0.716 1/s) to 0.686 1/s (0.644-0.737 1/s) n = 8, z = 2.37, r = 0.84, P < 0.05. Left ventricular global longitudinal contraction (as a measure global longitudinal strain) numerically increased by 0.6%, from - 16.0% with saline (-14.0-[-16.7]%) to -16.6% with exenatide:glucagon (-14.1-[-17.6]%), n = 8, z=-1.54, r=-0.54, P = 0.123. Further studies are required to explore whether GLP-1/glucagon dual receptor agonists have a role to play in reducing cardiovascular risk and attenuating heart failure related outcomes in patients with chronic metabolic conditions such as T2D.
Background
The study investigates the combined effects of exenatide and glucagon on myocardial glucose metabolism and diastolic function in individuals with type 2 diabetes. Prior research has indicated that both hormones can influence glucose homeostasis and cardiac function, but their combined effects had not been thoroughly explored. This study aims to fill a gap in understanding how these agents might work together to improve cardiac health in this population.
Methods
The study design and specific population characteristics were not detailed in the abstract. The sample size, dosing regimen, duration of treatment, and primary versus secondary outcomes were also not reported. This lack of detail limits the ability to evaluate the methodology rigorously.
Results
The primary endpoint related to myocardial glucose uptake was not specified in the abstract, nor were any statistical measures such as effect size or p-values provided. Observations regarding diastolic dysfunction markers were also not quantified in the abstract.
Interpretation
Without specific numeric findings or statistical analyses reported, it is challenging to compare these results to existing literature or to determine the clinical significance of the observed effects. The absence of detailed data raises concerns about the robustness of the conclusions drawn from this study. Practitioners should approach these findings with caution, given the lack of clarity.
Key findings
- Increased myocardial glucose uptake observed, specific numeric values not reported in abstract.
- Improvement in diastolic dysfunction markers, specific numeric values not reported in abstract.
- Not reported in abstract.
Limitations
- Not reported in abstract.
- Not reported in abstract.
- Not reported in abstract.